Wider social benefits should be considered by NICE - Gidley
Commenting on the news that two drug companies plan to apply for a judicial review of the way NICE reached its conclusion on the Alzheimer drug Donepezil, Liberal Democrat Health Spokesperson, Sandra Gidley MP said: